High-throughput analysis of ramelteon, agomelatine, and melatonin in human plasma by ultra-performance liquid chromatography–tandem mass spectrometry

Identification and quantitation of mifepristone and its N-demethyl metabolite in the plasma of an aborted fetus by liquid chromatography–quadrupole–time-of-flight–mass spectrometry (LC–Q–TOFMS) and ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS–MS)

“…The concentration of mifepristone in this study is estimated to be 1/100-1/1000 of the serum or plasma concentrations that the women administered; the relatively low concentration of mifepristone in the fetus may be due to the high binding to proteins in serum [3]. Using UPLC-MS-MS, our group has developed rapid and sensitive methods for determining drugs and poisons [20,21]; mifepristone, however, was not fully confirmed in this study. Single TOFMS [22] or matrix-assisted laser desorption ionization (MALDI)-TOF [23,24] techniques are useful for identifying poisons because of their high resolution.…”

Development and Validation of an UHPLC-UV method for the Determination of Agomelatine in Human Plasma and Serum Suitable for Routine Clinical Analysis

“…Up to date, to the best of our knowledge, four methods have been published for the determination of agomelatine in human plasma [5,6,8,9]. Two of the reported bioanalytical methods [5,6] employed a liquid-liquid extraction procedure and a time-costing evaporation process, and the linear ranges were relatively narrow, which are not adequate for the determination of this high variability drug.…”

“…The method of Li and colleagues that provides the detection of agomelatine and its metabolites in human plasma although has a simple sample preparation procedure it is based on the expensive LC-MS/MS instrumentation [9]. The high cost equipment is the main disadvantage of the UPLC-MS/MS method reported by Ogawa and colleagues [8] and the liquid chromatography-fluorimetric detection (HPLC-F) assay reported by Saracino and colleagues [7].…”

LC–MS/MS method for simultaneous determination of ramelteon and its metabolite M‐II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers

“…Few analytical methods have been reported for the determination of ramelteon. Tadashi Ogawa et al developed an UHPLC–MS/MS method for the determination of ramelteon with a lower limit of quantitation (LLOQ) of 0.500 ng/mL after solid‐phase extraction (Ogawa et al, ). The volume of plasma was up to 1.00 mL for preparation.…”